key: cord-0938667-g9eqr24w
authors: Balli, Nisa; Kara, Emre; Demirkan, Kutay
title: The Another Side of COVID‐19 in Alzheimer’s Disease Patients: Drug‐Drug Interactions
date: 2020-06-27
journal: Int J Clin Pract
DOI: 10.1111/ijcp.13596
sha: e198be657a7aa77124372255df3339724e1db127
doc_id: 938667
cord_uid: g9eqr24w

Coronavirus Disease 2019 (COVID‐19) outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has become a major public health problem. The elderly people are the most affected population by the COVID‐19 outbreak in terms of mortality and morbidity. Delirium caused by hypoxia, a prominent clinical feature of COVID‐19, may increase the need for treatment of Alzheimer's disease (AD) patients (1). Therefore, drug‐drug interactions should be considered in AD patients while receiving COVID‐19 treatment.

Coronavirus Disease 2019 (COVID-19) outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a major public health problem. The elderly people are the most affected population by the COVID-19 outbreak in terms of mortality and morbidity. Delirium caused by hypoxia, a prominent clinical feature of COVID-19, may increase the need for treatment of Alzheimer's disease (AD) patients (1) . Therefore, drug-drug interactions should be considered in AD patients while receiving COVID-19 treatment. Memantine undergoes limited hepatic metabolism and has a low risk for pharmacokinetic/pharmacodynamic drug-drug interaction. Therefore, memantine may be a safer alternative in COVID-19 treatment (2) .

This article is protected by copyright. All rights reserved QT interval prolongation and ventricular arrhythmias (including Torsades de Pointes) should be monitor in the use of azithromycin, CQ, HCQ and lopinavir/ritonavir with antipsychotics, antidepressants. Caution may be required when using strong CYP2D6 inhibitors (such as paroxetine and fluoxetine) and CYP2D6 substrate CQ (2, 3) .

In addition, glycemic control should be monitored as selective serotonin reuptake inhibitors may increase the hypoglycemic effect of CQ and HCQ (4) . Due to the effect of ritonavir on a large number of drug-metabolizing enzymes, the dose may need to be increased/decreased when used with antipsychotic and antidepressant drugs that may potentially affect their metabolism (3, 5) .

No potential interaction is expected between tocilizumab, ribavirin, favipiravir and AD' treatments (3) . Drug interactions should be evaluated in AD patient while receiving COVID-19 treatment. Principally, safer COVID-19 and AD treatments should be preferred, otherwise the patient should be closely monitored essential aspects.

Dementia care during COVID-19

Clinically relevant drug interactions with anti

Alzheimer's drugs

COVID-19 Drug Interactions

Drugs and hypoglycemia. Hypoglycemia--causes and occurrences. Shanghai: InTechOpen

Potential drug-drug interactions in Alzheimer patients with behavioral symptoms

Accepted Article

The authors declare they have no conflict of interest.This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

This article is protected by copyright. All rights reserved